Skip to content
Taxonomy
Exploring New Therapeutic Pathways for CMT1B: UPR Activation Researchers at the Ospedale San Raffaele (OSR) Scientific Institute in Read More
Advancing the Understanding of CMT2A and CMT2F: A Call to Beat CMT The Charcot-Marie-Tooth Association (CMTA), through its Strategy To Accelerate Research Read More
Let’s Beat CMT – 2024 CMT Awareness Month #LetsBeatCMT is a social media initiative during CMT Awareness Month Read More
CMTA-STAR Alliance Partner Actio Biosciences Receives FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Their Treatment in Development for CMT2C The Charcot-Marie-Tooth Association (CMTA) is pleased to share exciting news Read More
CMTA Alliance Partner Applied Therapeutics Plans to Submit an NDA for CMT-SORD, a Potential First Approval for the Treatment of any type of CMT The Charcot-Marie-Tooth Association (CMTA) is pleased to share exciting news Read More
Gene Replacement Therapy in CMT4 Subtypes The Charcot-Marie-Tooth Association (CMTA) has announced a $240K investment in Read More
Nanoparticles for CMT1A, CMT1B, and CMTX1: A New Frontier in Gene Therapy In a groundbreaking three-year joint project between the Charcot-Marie-Tooth Association Read More
Repurposing Drugs for CMT1A: An Encouraging Approach Charcot-Marie-Tooth disease type 1A (CMT1A) is the most common form Read More
DNA-Based Therapeutics: A Promising Future for CMT2E Treatment Researchers at the University of Miami, supported by the Charcot-Marie-Tooth Read More
CMT-SORD: Share Your Story CMT-SORD: What is Your Story? For many with CMT, the Read More